Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant

McGill University

$759,696.00

Reversal of neuronal and cerebrovascular pathology in Alzheimer's disease

FY 2012-13

Summary
Despite very active research on Alzheimer's disease (AD) over the past years, there is still very little to offer to patients as a choice of new therapy. It has been argued that this disappointing outcome is due to our poor understanding of the initial culprit of the disease. Several studies in patients indicate that a chronic reduction in blood supply to the brain occurs before the cognitive decline, and actually contributes to the neuronal failure. Dysfunctional blood vessels would impact on basic needs of the brain for fuel, and lead to neuronal injury, accumulation or faulty clearance of deleterious molecules and, ultimately, to neuronal degeneration. Studying the relationships between cerebrovascular pathology and memory deficit in AD using a classic mouse model of the disease, we found that it is possible to totally rescue both memory and brain perfusion. We also developed a new mouse model that recapitulates the full spectrum of neuronal, cognitive and cerebrovascular landmarks of the human disease. We will use these two models to better identify the relationships between cerebrovascular dysfunction and memory loss, and understand how drugs currently used for the treatment of cardiovascular diseases can rescue both deficits. We hypothesize that preserving a healthy cerebral circulation together with intact neuronal function will offer more effective treatments for AD. Further, we suggest that it is possible to rescue memory independently from reducing the levels of amyloid-beta, a highly toxic protein that accumulates in the brain of AD patients. Our goals are to identify the altered molecular pathways in brain and blood vessels that can be targeted therapeutically to concurrently rescue memory and brain perfusion.
Program
Operating Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
265937
Name
Hamel Edith
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Aging
Theme2
Biomedical
Prcname2
Cardiovascular System - C: Vascular System
Projecttitle
Reversal of neuronal and cerebrovascular pathology in Alzheimer's disease
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$759,696
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Alzheimer'S Disease; Angiotensin Type 1 Receptor Antagonist; Animal Models; Cerebral Circulation; Memory; Statin
Abstract
Despite very active research on Alzheimer's disease (AD) over the past years, there is still very little to offer to patients as a choice of new therapy. It has been argued that this disappointing outcome is due to our poor understanding of the initial culprit of the disease. Several studies in patients indicate that a chronic reduction in blood supply to the brain occurs before the cognitive decline, and actually contributes to the neuronal failure. Dysfunctional blood vessels would impact on basic needs of the brain for fuel, and lead to neuronal injury, accumulation or faulty clearance of deleterious molecules and, ultimately, to neuronal degeneration. Studying the relationships between cerebrovascular pathology and memory deficit in AD using a classic mouse model of the disease, we found that it is possible to totally rescue both memory and brain perfusion. We also developed a new mouse model that recapitulates the full spectrum of neuronal, cognitive and cerebrovascular landmarks of the human disease. We will use these two models to better identify the relationships between cerebrovascular dysfunction and memory loss, and understand how drugs currently used for the treatment of cardiovascular diseases can rescue both deficits. We hypothesize that preserving a healthy cerebral circulation together with intact neuronal function will offer more effective treatments for AD. Further, we suggest that it is possible to rescue memory independently from reducing the levels of amyloid-beta, a highly toxic protein that accumulates in the brain of AD patients. Our goals are to identify the altered molecular pathways in brain and blood vessels that can be targeted therapeutically to concurrently rescue memory and brain perfusion.
Competitiondate
201209
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Hamel, Edith
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $759,696~ $0~